These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 28003217)

  • 21. Telavancin for Acute Bacterial Skin and Skin Structure Infections, a Post Hoc Analysis of the Phase 3 ATLAS Trials in Light of the 2013 FDA Guidance.
    Pushkin R; Barriere SL; Wang W; Corey GR; Stryjewski ME
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6170-4. PubMed ID: 26248356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections.
    Beresford E; Biek D; Jandourek A; Mawal Y; Riccobene T; Friedland HD
    Expert Rev Clin Pharmacol; 2014 Mar; 7(2):123-35. PubMed ID: 24494793
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2012 Jun; 73(6):856-64. PubMed ID: 22687813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. End points in hospital-acquired pneumonia and/or ventilator-associated pneumonia clinical trials: food and drug administration perspective.
    Laessig KA
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S117-9. PubMed ID: 20597659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improving Conduct and Feasibility of Clinical Trials to Evaluate Antibacterial Drugs to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team.
    Knirsch C; Alemayehu D; Botgros R; Comic-Savic S; Friedland D; Holland TL; Merchant K; Noel GJ; Pelfrene E; Reith C; Santiago J; Tiernan R; Tenearts P; Goldsack JC; Fowler VG
    Clin Infect Dis; 2016 Aug; 63 Suppl 2():S29-36. PubMed ID: 27481950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of U.S. Food and Drug Administration-Approved Antibiotics, 2010-2015.
    Deak D; Outterson K; Powers JH; Kesselheim AS
    Ann Intern Med; 2016 Sep; 165(5):363-72. PubMed ID: 27239977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical trial design for mild-to-moderate community-acquired pneumonia--an industry perspective.
    Echols RM; Tillotson GS; Song JX; Tosiello RL
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S166-75. PubMed ID: 18986284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. End points in dermatologic clinical trials: A review for clinicians.
    Wei EX; Kirsner RS; Eaglstein WH
    J Am Acad Dermatol; 2016 Jul; 75(1):203-9. PubMed ID: 26936300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.
    Scott LJ
    Drugs; 2015 Jul; 75(11):1281-91. PubMed ID: 26105117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. When are "positive" clinical trials in oncology truly positive?
    Ocana A; Tannock IF
    J Natl Cancer Inst; 2011 Jan; 103(1):16-20. PubMed ID: 21131576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oritavancin, a single-dose, complete regimen, for the treatment of acute bacterial skin and skin structure infections.
    Wu G; Truong J; Lee S; Elnadoury O; Kuan W; Abraham T; Wu A; Liu M
    Expert Rev Anti Infect Ther; 2015 Apr; 13(4):409-16. PubMed ID: 25661747
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.
    File TM; Rewerska B; Vucinic-Mihailovic V; Gonong JRV; Das AF; Keedy K; Taylor D; Sheets A; Fernandes P; Oldach D; Jamieson BD
    Clin Infect Dis; 2016 Oct; 63(8):1007-1016. PubMed ID: 27448679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The FDA outlook of events reporting after ticagrelor or clopidogrel in the PLATO Trial: impact of sponsor censoring dates, drug discontinuation, and withdrawal of consent.
    Serebruany VL
    Cardiology; 2011; 120(3):169-71. PubMed ID: 22418766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification and content validation of wound therapy clinical endpoints relevant to clinical practice and patient values for FDA approval. Part 1. Survey of the wound care community.
    Driver VR; Gould LJ; Dotson P; Gibbons GW; Li WW; Ennis WJ; Kirsner RS; Eaglstein WH; Bolton LL; Carter MJ
    Wound Repair Regen; 2017 May; 25(3):454-465. PubMed ID: 28370922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in elderly patients.
    Udeani G; Evans J; Cole P; Friedland HD
    Hosp Pract (1995); 2014 Aug; 42(3):109-15. PubMed ID: 25255412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Developing drugs for treatment of atopic dermatitis in children (≥3 months to <18 years of age): Draft guidance for industry.
    Siegfried EC; Jaworski JC; Eichenfield LF; Paller A; Hebert AA; Simpson EL; Altman E; Arena C; Blauvelt A; Block J; Boguniewicz M; Chen S; Cordoro K; Hanna D; Horii K; Hultsch T; Lee J; Leung DY; Lio P; Milner J; Omachi T; Schneider C; Schneider L; Sidbury R; Smith T; Sugarman J; Taha S; Tofte S; Tollefson M; Tom WL; West DP; Whitney L; Zane L
    Pediatr Dermatol; 2018 May; 35(3):303-322. PubMed ID: 29600515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overview of recent studies of community-acquired pneumonia.
    Higgins K; Singer M; Valappil T; Nambiar S; Lin D; Cox E
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S150-6. PubMed ID: 18986282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval.
    Naci H; Wouters OJ; Gupta R; Ioannidis JPA
    Milbank Q; 2017 Jun; 95(2):261-290. PubMed ID: 28589600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections.
    Huang DB; Corey GR; Holland TL; Lodise T; O'Riordan W; Wilcox MH; File TM; Dryden M; Balser B; Desplats E; Torres A
    Int J Antimicrob Agents; 2018 Aug; 52(2):233-240. PubMed ID: 29783024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic and pharmacodynamic evaluation of ceftaroline fosamil.
    Merker A; Danziger LH; Rodvold KA; Glowacki RC
    Expert Opin Drug Metab Toxicol; 2014 Dec; 10(12):1741-50. PubMed ID: 25347329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.